NeuroSense Therapeutics Ltd. (NRSN)
| Market Cap | 28.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.13M |
| Shares Out | 35.35M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 381,793 |
| Open | 0.800 |
| Previous Close | 0.751 |
| Day's Range | 0.750 - 0.860 |
| 52-Week Range | 0.630 - 2.600 |
| Beta | 1.68 |
| Analysts | Strong Buy |
| Price Target | 8.50 (+950.81%) |
| Earnings Date | Mar 31, 2026 |
About NRSN
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical stu... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for NRSN stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 950.81% from the latest price.
News
NeuroSense Announces Pricing of Insider-Led PIPE Financing
Financing led by CEO Alon Ben-Noon and CFO Or Eisenberg, alongside participation from an existing significant shareholder CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
Patent Protection Through October 2042 Follows prior patent grants in the U.S. and Australia Further strengthens NeuroSense's global intellectual property portfolio CAMBRIDGE, Mass., April 6, 2026 /PR...
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requireme...
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS Statistically significant survival benefit demonstrated, including 65% reduction in risk of de...
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
CAMBRIDGE, Mass., March 24, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial" CAMBRIDGE, Mass., March 18, 2026 /PR...
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower func...
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference
CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS
CAMBRIDGE, Mass., Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
Strengthens Global IP Portfolio for PrimeC Through 2042 CAMBRIDGE, Mass., Feb. 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease
Patent protection extended through 2043 Alzheimer's proof-of-concept study completed Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 21, 2026 /PRNewswire/ -- NeuroSense Ther...
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB
Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study
Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026 CAMBRIDGE, Mass. , Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Transcript: Status Update
PARAGON phase III ALS trial is set to begin mid-2026, with FDA clearance and global enrollment plans. New data and biomarkers will support regulatory submissions, while partnership and financing efforts are ongoing. The Alzheimer's program has completed phase II data collection, with results expected in Q1 2026.
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026
CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
CAMBRIDGE, Mass. , Nov. 24, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense to Host Investor Webinar on December 8, 2025
Business, regulatory and clinical updates will be provided CAMBRIDGE, Mass. , Nov. 3, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers
CAMBRIDGE, Mass. , Oct. 6, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
Initial Phase 2 RoAD trial results demonstrate improvements in brain-cell connectivity and health, with a favorable safety profile CAMBRIDGE, Mass. , Sept. 10, 2025 /PRNewswire/ -- NeuroSense Therapeu...
NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price
Financing at 40% premium to market price provides near-term bridge to anticipated milestones CAMBRIDGE, Mass. , Sept. 4, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
NeuroSense Provides Business Update and Progress for the First Half of 2025
CAMBRIDGE, Mass. , July 31, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd.
Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community
Live Broadcast: Award-Winning Actor & ALS Advocate Aaron Lazar hosts NeuroSense CEO Alon Ben-Noon to Unveil New Insights into NeuroSense's Breakthrough Science, Canadian Regulatory Milestones & Go-to-...
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
Last Wednesday, NeuroSense Therapeutics Ltd. NRSN said it scaled up its production of PrimeC to a commercial scale.
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
NeuroSense Announces Global CDMO Selection and Manufacturing Scale-Up, Enabling Rapid Pathway to Commercialization for What is Projected to be a $100-150M Canadian Market Opportunity CAMBRIDGE, Mass. ...
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update
Letter outlines Phase 3 timeline for PrimeC in ALS, provides update on Canadian regulatory pathway and strategic partnership discussions; Company optimistic about ongoing partnership discussions with ...